Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aplastic anaemia: management.

S B Killick1, J C Marsh

  • 1Department of Haematology, St George's Hospital Medical School, Cranmer Terrace, London, SW17 ORE, UK.

Blood Reviews
|September 15, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: Possible overestimation of isomer depletion due to contamination.

Nature·2021
Same author

Isomer depletion as experimental evidence of nuclear excitation by electron capture.

Nature·2018
Same author

Highlights of the 19th Annual Meeting of the International Society for Experimental Hematology (ISEH) Held in Seattle, Washington, USA, August 26-30, 1990.

Leukemia & lymphoma·2016
Same author

Management of Aplasia.

Hematology (Amsterdam, Netherlands)·2016
Same author

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

Bone marrow transplantation·2015
Same author

Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.

Bone marrow transplantation·2013
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Aplastic anemia (AA) treatment involves choosing between stem cell transplantation (SCT) or immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and cyclosporin A (CSA). SCT offers higher cure rates, while IST has risks of relapse and transformation.

Area of Science:

  • Hematology
  • Immunology

Background:

  • Acquired aplastic anemia (AA) is a rare, life-threatening hematologic disorder requiring urgent supportive care.
  • Severe AA necessitates interventions to prevent sepsis and hemorrhage.

Purpose of the Study:

  • To outline treatment options for aplastic anemia.
  • To compare the efficacy and risks of allogeneic stem cell transplantation (SCT) versus immunosuppressive therapy (IST).

Main Methods:

  • Review of current therapeutic strategies for aplastic anemia.
  • Comparison of outcomes between SCT and IST, including cure rates and long-term risks.

Main Results:

  • HLA-identical sibling SCT achieves 75-90% long-term cure rates.
  • IST with ATG and CSA shows improving results, but carries risks of relapse and clonal transformation.

Related Experiment Videos

  • Use of hematopoietic growth factors in AA is controversial, with potential toxicity noted.

    • Conclusions:

    • Allogeneic SCT from HLA-identical siblings offers the best chance for cure in aplastic anemia.
    • Immunosuppressive therapy is an alternative but associated with significant long-term risks.
    • Ongoing improvements in supportive care enhance outcomes for IST non-responders.